Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13305883 | 1.00 | JAK3 (0.36) | JAK3ROCK2FGFR3JAK2DDR1 | |
| SCHEMBL10044712 | 0.92 | JAK3 (0.36) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL13305882 | 0.92 | JAK3 (0.36) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL10044717 | 0.87 | FGFR3 (0.37) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL10044752 | 0.87 | FGFR3 (0.37) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL10044708 | 0.86 | FGFR3 (0.36) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL10072160 | 0.85 | ROCK2 (0.41) | JAK3ROCK2JAK2MAP3K7TAB1 | |
| SCHEMBL10044735 | 0.84 | FGFR3 (0.37) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL10044728 | 0.83 | MCHR1 (0.34) | JAK3ROCK2FGFR3JAK2 | |
| SCHEMBL13305879 | 0.83 | MCHR1 (0.34) | JAK3ROCK2FGFR3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | JAK3 3/4885ROCK2 244/4885FGFR3 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.